Latest News
BC Bud Corp (BCBC.C) breathes new life into the cannabis space, up 3x in two months
Top 5 Gainers and Losers: TMQ.TO, GLM.CN, AGMR.V
Standard Uranium (STND.V) reports on exploration at Sun Dog Project
Top 5 Gainers and Losers: BLO.CN, DKL.V, MMG.V
Bitcoin bulls beware! Topping pattern to trigger more downside?
Top 5 Gainers and Losers: NUMI.TO, FOBI.V, IDK.CN
Medexus Pharmaceuticals (MDP.T) CEO picks up the gauntlet
In today’s episode, Equity.Guru founder, Chris Parry, talks with Ken d’Entremont, CEO and director of Medexus Pharmaceuticals, and asks about the company’s recent strong financials, the possible inclusion of treosulfan into the company’s portfolio and what growth potential investors can expect over the next 12 months.
Enjoy!
Related Posts
Potential of Medexus Pharmaceuticals: Chris Parry gets into what investors are missing
Medexus Pharma (MDP.TO) Breaks Records: A Deep Dive into Quarterly Earnings, Portfolio Growth, and Future Opportunities
Medexus Pharmaceuticals (MDP): A Roller Coaster Ride to Success
Medexus Pharmaceuticals Sets New Revenue Records and Continues Expansion with Innovative Products and Financing
Medexus Pharmaceuticals (MDP.T) deals with its debentures
Medexus CEO (MDP.T) on creating Canada’s specialty pharma success story
More on MDP.T
Potential of Medexus Pharmaceuticals: Chris Parry gets into what investors are missing
Medexus Pharma (MDP.TO) Breaks Records: A Deep Dive into Quarterly Earnings, Portfolio Growth, and Future Opportunities
Medexus Pharmaceuticals (MDP): A Roller Coaster Ride to Success
Medexus Pharmaceuticals Sets New Revenue Records and Continues Expansion with Innovative Products and Financing
Medexus Pharmaceuticals (MDP.T) deals with its debentures
Medexus CEO (MDP.T) on creating Canada’s specialty pharma success story